Abstract: This invention is directed to sorbitol dehydrogenase inhibitory compounds of the formula I,
wherein R1, R2 and R3 are as defined in the specification. This invention is also directed to pharmaceutical compositions containing those compounds and methods of treating or preventing diabetic complications, particularly diabetic neuropathy, diabetic nephropathy, diabetic microangiopathy, diabetic macroangiopathy and diabetic cardiomyopathy by administering such compounds to a mammal suffering from diabetes and therefore at risk for developing such complications. This invention is also directed to pharmaceutical compositions comprising a combination of a compound of formula I of this invention with an aldose reductase inhibitor and to methods of treating or preventing diabetic complications therewith.
Type:
Grant
Filed:
March 29, 2000
Date of Patent:
July 2, 2002
Assignee:
Pfizer Inc.
Inventors:
Margaret Y. Chu-Moyer, Banavara L. Mylari, William J. Zembrowski
Abstract: The invention provides a child-resistant apparatus for dispensing articles which comprises a housing for retaining a blister package wherein the, housing comprises a dispensing aperture; optionally, but preferably, a blister package comprising at least one blister cell containing an article to be dispensed; and a substantially rigid backing sheet substantially co-extensive with, and substantially blocking, the dispensing aperture wherein the backing sheet comprises exposed end portions, such that pressure applied on either exposed end portion individually, or on both exposed end portions simultaneously of the backing sheet, imparts arcuate flexure thereto and dislocation thereof from the substantially co-extensive, and substantially blocking position, to a position where the dispensing aperture is unblocked permitting the article contained in the blister cell to be dispensed.
Abstract: Compounds of the formula
where W is
are particularly useful in treating migraine and other disorders, such as depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, pain and chronic paroxysmal hemicrania and headache associated with vascular disorders. The compounds can also be used as centrally acting antihypertensives and vasodilators.
Abstract: Compounds of the formula
and their pharmaceutically acceptable salts, wherein R1, R2, and R3 are defined as in the specification, intermediates in the synthesis of such compounds. pharmaceutical compositions containing such compounds and methods of using such compounds, in the treatment of neurological and psychological disorders.
Abstract: The present invention provides novel processes for preparing 3(S)-[(5-chloro-1H-indole-2-carbonyl)-amino]-2(R)-hydroxy-4-phenyl-butyric acid. Also provided are novel intermediates used in those processes. Further, the 3(S)-[(5-chloro-1H-indole-2-carbonyl)-amino]-2(R)-hydroxy-4-phenyl-butyric acid prepared by the novel processes can be further reacted to yield known indole 2-carboxamides and derivatives thereof possessing glycogen phosphorylase inhibitory activity, which are useful in the treatment of mammals, especially human beings, having glycogen phosphorylase dependent diseases or conditions.
Type:
Grant
Filed:
May 5, 2000
Date of Patent:
June 25, 2002
Assignee:
Pfizer Inc.
Inventors:
Keith M. DeVries, Darrell E. Fox, Philip D. Hammen, Dennis J. Hoover, Jeffrey B. Jorgensen
Abstract: The present invention relates to avian cell lines which efficiently support the growth and productive infection of Marek's Disease Virus at high titers. The present invention also relates to avian cell lines which have been engineered to support the growth and productive infection of recombinant Marek's Disease Virus at high titers. The present invention relates a process for the preparation of Marek's Disease Virus in quantities suitable for vaccine purposes.
Abstract: The present invention is directed to a method of producing attenuated forms of bovine viral diarrhea (BVD) virus by mutating the Npro protease gene. The invention includes the attenuated viruses made by this method, antibodies generated using these viruses, and vaccines that can be used for immunizing cattle.
Abstract: The present invention relates to compounds of formula I,
and to their pharmaceutically acceptable salts. Compounds of formula I exhibit activity as serotonin, norepinephrine, and dopamine reuptake inhibitors and can be used in the treatment of central nervous system and other disorders.
Abstract: The present invention is directed to a method of producing attenuated forms of bovine viral diarrhea (BVD) virus by mutating the Npro protease gene. The invention includes the attenuated viruses made by the method, antibodies generated using these viruses, and vaccines that can be used for immunizing cattle.
Abstract: A “one-pot” process is described herein for the production of pyrazole compounds of general formula (II)
comprising the steps of reacting a compound of general formula (III)
with an acylating agent in the presence of a base and an optional activating agent followed by the addition of a hydrazine compound in situ.
Type:
Grant
Filed:
July 6, 2001
Date of Patent:
June 18, 2002
Assignee:
Pfizer Inc.
Inventors:
Laurence James Harris, Philip Charles Levett
Abstract: The compound
is a neuropeptide Y antagonist and is effective in treating feeding disorders, cardiovascular diseases and other physiological disorders.
Type:
Grant
Filed:
January 28, 2000
Date of Patent:
June 18, 2002
Assignee:
Pfizer Inc.
Inventors:
Philip A. Carpino, Marlys Hammond, Richard F. Hank
Abstract: There is provided compounds of formula IA and of formula IB,
wherein R1, R2, R3, R4 and A have meanings given in the description, which are useful in the curative and prophylactic treatment of a medical condition for which inhibition of a cyclic guanosine 3′,5′-monophosphate phosphodiesterase (e.g. cGMP PDE5) is desired.
Type:
Grant
Filed:
October 22, 1999
Date of Patent:
June 18, 2002
Assignee:
Pfizer Inc.
Inventors:
Mark Edward Bunnage, John Paul Mathias, Stephen Derek Albert Street, Anthony Wood
Abstract: This invention relates to compounds of the formula
and to pharmaceutically acceptable salts thereof. The compounds of formula 1 are potent antibacterial agents that may be used to treat various bacterial infections and disorders related to such infections. The invention also relates to pharmaceutical compositions containing the compounds of formula 1 and to methods of treating bacterial infections by administering the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1 and to intermediates useful in such preparation.
Type:
Grant
Filed:
February 16, 2000
Date of Patent:
June 18, 2002
Assignee:
Pfizer Inc
Inventors:
Brian Scott Bronk, Takushi Kaneko, Michael Anthony Letavic, Hengmaio Cheng, Edward Alan Glazer, Bingwei Vera Yang
Abstract: Compounds of formula (I), their salts and prodrugs thereof, where the substituents are as defined herein are disclosed as opiate binding agents useful in the treatment of opiate-mediated conditions. Also described are processes for making such substances.
Type:
Application
Filed:
October 30, 2001
Publication date:
June 13, 2002
Applicant:
Pfizer Inc.
Inventors:
Bernard Joseph Banks, Robert James Crook, Stephen Paul Gibson, Graham Lunn, Alan John Pettman
Abstract: The present invention relates to compounds of the formula
wherein R1, R2, R3, X, Y and the dashed line are defined as in the specification, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. These compounds are useful as psychotherapeutic agents.
Abstract: Compounds of the formula
wherein R1, R2, R3, R4, R5 and R6 are as described in the specification are useful to treat inflammation and other immune disorders.
Type:
Grant
Filed:
May 18, 2000
Date of Patent:
June 11, 2002
Assignee:
Pfizer Inc.
Inventors:
John Charles Kath, Matthew Frank Brown, Christopher Stanley Poss
Abstract: The invention relates to a method of preparing a macrolide antibiotic of the formula
wherein R1, R2, R3, R4, R5 are defined above. These antibiotics are useful as antibacterial and antiprotozoal agents in mammals, including man, as well as in fish and birds. The invention also includes novel compounds made by the preparation of the macrolide antibiotic.
Type:
Grant
Filed:
July 5, 2000
Date of Patent:
June 11, 2002
Assignee:
Pfizer Inc.
Inventors:
David H. B. Ripin, Brian C. Vanderplas, Takushi Kaneko, William T. McMillen, Robert W. McLaughlin
Abstract: The present invention provides novel methods of inhibiting pathological conditions related to organ systems which respond to estrogen agonists comprising administering to a mammal in need of such treatment an effective amount of a compound of formula I
Abstract: A child-resistant apparatus for dispensing articles which comprises a housing for retaining a blister package wherein the housing comprises a dispensing aperture; optionally, but preferably, a blister package comprising at least one blister cell containing an article to be dispensed; and a substantially rigid backing sheet substantially co-extensive with, and substantially blocking, the dispensing aperture, such that pressure exerted on an exposed top edge of the backing sheet imparts arcuate flexure thereto and dislocation thereof from the substantially co-extensive, and substantially blocking position, to a position where the dispensing aperture is unblocked permitting the at least one article contained in the at least one blister cell to be dispensed. Release of pressure on the exposed top edge of the backing sheet relaxes flexure thereof such that the substantially co-extensive, and substantially blocking position, wherein the backing sheet substantially blocks the dispensing aperture, is restored.